Genpharmasec share price
BSE: 531592Commercial Services & SuppliesSmall Cap
GENPHARMASEC LIMITED · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1996
Last close ₹0.99₹0.00 (0.00%)
Share price at the BSE close on 27 Oct 2026. Previous close ₹0.99.
27 Oct: open ₹1.01, high ₹1.01, low ₹0.98
52-week range of traded prices to 27 Oct 2026
₹0.75Low, 30 Mar 2026₹1.84High, 27 Oct 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹55 Cr3,222nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.83
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −1.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.50
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 1,38,066
Results
Standalone, as consolidated accounts are on record for only 3 of the last ten years; ₹ crore.Genpharmasec quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +337.8%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- –
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹45 Crdown 13.32%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹1.57 Crdown 32.29%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 3.5%
Revenue by quarter
Peak revenue ₹52 Cr, quarter to Mar 2026; lowest ₹5.77 Cr, quarter to Sep 2024
Net profit by quarter, a loss in red
- Net profit
- Loss
A loss in 1 of the 8 quarters shown
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.8 | 8.3 | 13.6 | 12.1 | 31.6 | 36.0 | 51.7 | 44.8 |
| Net profit | 1.0 | 1.1 | −0.2 | 1.6 | 0.8 | 0.8 | 2.3 | 1.6 |
| Net margin | 17.3% | 13.5% | −1.7% | 12.9% | 2.6% | 2.1% | 4.5% | 3.5% |
Standalone. The last eight quarters. The latest is shaded.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹131 Crup 298.47%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹5.45 Crup 120.74%
- Net margin
- 4.1%
Revenue by year
Peak revenue ₹131 Cr, year to Mar 2026; lowest ₹0.08 Cr, year to Mar 2018
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 1 of the 10 years shown
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 17 | 21 | 27 | 26 | 30 | 33 | 131 |
| Net profit | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 2 | 5 |
| Net margin | 2.7% | 63.4% | 61.6% | 6.1% | 5.9% | −0.8% | 4.4% | 0.2% | 7.5% | 4.1% |
Standalone. Years to March. The latest is shaded.
Business segments
Share of revenue, year to Mar 2026, consolidated.Segment revenue and profit
- PharmaceuticalsPharmaceuticals, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹131 Crup 301.99%93.5%
- Manufacturing & ProcessingManufacturing & Processing, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹8 Cr5.8%
- Laboratory TestingLaboratory Testing, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹1 Crdown 13.63%0.7%
The pill is the change in revenue on the year before; the share is of all the businesses together.
Valuation
Today, against the company's own history. Not shown, P/E: a results filing in the last twelve months restated the quarters before it inside its year to date, so the four quarters as the company reported them do not add to a twelve-month profit; the ratio returns once the trailing year no longer holds a quarter from before the restatement. Dividend yield is not shown: no dividend in the years on record.Genpharmasec PE ratio and valuation
Price to book
At or below today's level on 1% of 1,136 trading days over the last 5 years.
LowestHighest
Its median5.79Industry median1.13
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −58.7% | +120.7% | −81.3% | 0.0% |
| 3 years | −36.9% | +35.7% | −53.5% | 0.0% |
| 5 years | −37.2% | +16.7% | −46.2% | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1 and 5 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Promoter and insider buying and selling
Trades made since 28 Oct 2025.Genpharmasec insider trading
Bought on the marketBought on the market. The value each filer stated for its purchases on the exchange, added up; gifts, transfers and pledges are not counted. A purchase filed with no value is counted under the sum, not in it. Sold on the marketSold on the market. The value each filer stated for its sales on the exchange, added up; gifts, transfers and pledges are not counted. A sale filed with no value is counted under the sum, not in it.
- Promoters and promoter group2 purchases, 0 sales₹1.22 CrNo saleNetNet. The value bought on the market less the value sold, over the trades whose filers stated a value.₹1.22 Cr
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Genpharmasec competitors and peers
Trading & Distributors, 196 listed companies, priced on 27 Oct 2026. The table lists the 8 companies closest to Genpharmasec in market cap. 1 company in the table last traded before then: its row is priced on its last trade.Services companies
Genpharmasec is not on the chart: it has no P/E or return on equity today
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Constronics InfraCONSTRONIC | 57 | 22.84 | 1.38 | – | – | 6.3% | 3.6% | 0.00% |
 Ganesha EcoverseGANVERSE | 57 | – | 1.59 | −95.0% | – | −13.6% | −14.2% | 0.00% |
 Fortune InternationalFORINTL | 56 | 14.46 | 1.18 | – | −13.6% | 8.5% | −0.5% | 0.00% |
 Minal IndustriesMINALIND | 56 | 150.31 | 1.05 | −6.0% | – | 0.7% | 0.0% | 0.00% |
| Hira AutomobilesHIRAUTO | 53 | – | 3.60 | −32.6% | −270.0% | −8.4% | 6.3% | 0.00% |
 Dhanlaxmi CotexDHANCOT | 51 | – | 0.74 | +46.1% | – | – | −2.1% | 0.00% |
 Ramgopal PolytexRAMGOPOLY | 49 | – | 4.70 | +45.5% | – | −2.8% | −9.9% | 0.00% |
 Bombay Metrics Supply ChainBMETRICS | 49 | 29.79 | 2.30 | −8.7% | −63.3% | 8.2% | – | 0.25% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Genpharmasec announcements
Oct 2026
14 Oct · Intimation Regarding Change Of Name Of Subsidiary Of The Company
Sep 2026
Genpharmasec share price by year
Each calendar year to 2025.Genpharmasec share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 1.31 | −57.5% | 3.41 | 1.31 |
| 2024 | 3.08 | −34.0% | 8.71 | 1.93 |
| 2023 | 4.67 | +12.8% | 5.10 | 2.77 |
| 2022 | 4.14 | −21.1% | 10.08 | 3.87 |
| 2021 | 5.25 | −51.4% | 11.26 | 5.24 |
| 2020 | 10.80 | −18.2% | 15.85 | 10.21 |
| 2019 | 13.20 | +1.0% | 17.25 | 9.70 |
| 2018 | 13.07 | +187.3% | 13.07 | 3.52 |
| 2017 | 4.55 | +166.9% | 5.10 | 2.05 |
| 2016 | 1.71 | – | 1.71 | 1.31 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2018 is from its first session, 7 Feb 2018. 2016 is from its first session, 20 Dec 2016. The 2017 close is its last trade, on 17 Nov 2017.
Recent sessions
The 9 trading days to 26 Oct 2026, as traded on BSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 26 Oct 2026 | 1.00 | 1.02 | 0.98 | 0.99 | 1.00 | 1,85,005 |
| 23 Oct 2026 | 0.99 | 1.02 | 0.96 | 0.99 | 0.99 | 4,22,891 |
| 22 Oct 2026 | 0.96 | 1.02 | 0.94 | 1.02 | 0.97 | 5,25,755 |
| 21 Oct 2026 | 1.01 | 1.03 | 0.96 | 0.99 | 0.99 | 6,95,510 |
| 19 Oct 2026 | 1.06 | 1.09 | 1.01 | 1.01 | 1.02 | 10,97,244 |
| 16 Oct 2026 | 1.00 | 1.14 | 0.99 | 1.07 | 1.05 | 6,87,960 |
| 15 Oct 2026 | 1.01 | 1.01 | 0.99 | 1.00 | 1.00 | 2,40,640 |
| 14 Oct 2026 | 1.02 | 1.02 | 0.99 | 1.02 | 1.01 | 1,81,459 |
| 13 Oct 2026 | 1.00 | 1.02 | 0.99 | 1.00 | 1.00 | 5,68,110 |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 9 Jan 2024 | Rights issue | – | Shareholders were offered new shares. Noted, not adjusted for. |
| 9 Jan 2024 | Price move | – | A corporate action went ex within three days of this move (Right Issue of Equity Shares, ex-date 9 Jan 2024), and its terms do not account for the move. Not adjusted for. |
| 11 Apr 2019 | Split | 0.1000 | Each share became 10. |
| 20 Dec 2016 | Price move | – | This is the share's first trade after a corporate action (Reduction of Capital, ex-date 3 Aug 2016), and the action's terms do not account for the move. Earlier prices are not shown. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout. Where an event has no factor that can be worked out, the chart leaves out the closes before it. Any other event is noted and not adjusted for.
Company details
- BSE code
- 531592
- ISIN
- INE861N01036
- Industry
- Commercial Services & Supplies
- Website
- www.genpharmasec.com
- CIN
- L24231MH1992PLC323914
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1992
- Registered office
- Office No. 104 & 105 (1st Floor), Gundecha Industrial Premises Co-Operative Society Ltd., Akurli Road, Kandivali (East), Mumbai 400101, Maharashtra
- Share registrar
- Satellite Corporate Services Pvt Ltd
- Keeps the register of shareholders and handles transfers and dividend payments